Needham analyst James Ricchiuti reiterates Coherent (NASDAQ:COHR) with a Buy and maintains $58 price target.
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu